A randomized clinical trial comparing three fixed combinations of bimatoprost with timolol in patients with open-angle glaucoma or ocular hypertension

References

• Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11):2081–2090.
   PubMed Web of Science ®Google Scholar
• Lu LJ, Tsai JC, Liu J. Novel pharmacologic candidates for treatment of primary Open-Angle glaucoma. Yale J Biol Med. 2017;90(1):111–118.
   PubMed Web of Science ®Google Scholar
• Russo A, Riva I, Pizzolante T, et al. Latanoprost ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol. 2008;2(4):897–905.
   PubMedGoogle Scholar
• Sambhara D, Aref AA. Glaucoma management: relative value and place in therapy of available drug treatments. Ther Adv Chronic Dis. 2014;5(1):30–43.
   PubMedGoogle Scholar
• Costagliola C, Prete AD, Incorvaia C, et al. Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2001;239(11):809–814.
   PubMed Web of Science ®Google Scholar
• Cvenkel B, Kolko M. Current medical therapy and future trends in the management of glaucoma treatment. J Ophthalmol. 2020;2020:6138132.
   PubMed Web of Science ®Google Scholar
• European Glaucoma Society. 2014. Terminology and guidelines for glaucoma. 4th edn. Savona: PubliComm.
   Google Scholar
• Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma. 2008;17(3):211–216.
   PubMed Web of Science ®Google Scholar
• Brief G, Lammich T, Nagel E, et al. Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment. Clin Ophthalmol. 2010;4:1125–1129.
   PubMedGoogle Scholar
• Hommer A, Ganfort Investigators Group I A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(1):53–62.
   PubMed Web of Science ®Google Scholar
• Feuerhake C, Buchholz P, Kimmich F. Efficacy, tolerability and safety of the fixed combination of bimatoprost 0.03% and timolol 0.5% in a broad patient population: multicenter, open-label observational study. Curr Med Res Opin. 2009;25(4):1037–1043.
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. lin Ophthalmol. 2009;4:1–9.
   Google Scholar
• Gutierrez-Diaz E, Silva Cotta J, Muñoz-Negrete FJ, et al. Bimatoprost/timolol fixed combination versus latanoprost in treatment-naïve glaucoma patients at high risk of progression: a pilot study. Clin Ophthalmol. 2014;8:725–732.
   PubMedGoogle Scholar
• Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22(1):5–18.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Hakkola J, Pelkonen O, et al. Metabolism of ophthalmic timolol: new aspects of an old drug. Basic Clin Pharmacol Toxicol. 2011;108(5):297–303.
   PubMed Web of Science ®Google Scholar
• Pratt NL, Ramsay EN, Kalisch Ellett LM, et al. Association between ophthalmic timolol and hospitalisation for bradycardia. J Ophthalmol. 2015;2015:567387.
   PubMed Web of Science ®Google Scholar
• Quaranta L, Katsanos A, Floriani I, et al. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52(10):1552–1557.
   PubMed Web of Science ®Google Scholar
• Rolle T, Curto D, Alovisi C, et al. Timogel® vs timolol 0.5% ophthalmic solution: efficacy, safety, and acceptance. Eur J Ophthalmol. 2012;22(1):28–33.
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Niño J, Tahvanainen K, et al. Efficacy and systemic side-effects of topical 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Acta Ophthalmol Scand. 2005;83(6):723–728.
   PubMedGoogle Scholar
• Chiou SH, Hsu WM, Liu JH, et al. Comparative study of timolol gel versus timolol solution for patients with glaucoma. Zhonghua Yi Xue Za Zhi (Taipei). 2000;63(10):737–743.
   PubMedGoogle Scholar
• Ling Z, Zhang M, Hu Y, et al. Safety and efficacy of bimatoprost/timolol fixed combination in chinese patients with open-angle glaucoma or ocular hypertension. Chin Med J (Engl). 2014;127(5):905–910.
   PubMed Web of Science ®Google Scholar
• Allergan. GANFORT 0.3 mg/ml + 5 mg/ml eye drops, solution, in single-dose container; 2018.
   Google Scholar
• Shim SH, Kim JM, Choi CY, et al. Diurnal intraocular pressure with bimatoprost/timolol fixed combination versus latanoprost/timolol fixed combination in healthy subjects. Korean J Ophthalmol. 2014;28(1):39–48.
   PubMedGoogle Scholar
• Rigollet JPK, Ondategui JA, Pasto A, et al. Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol. 2011;5:187–191.
   PubMedGoogle Scholar
• Woodward DF, Krauss AH-P, Chen J, et al. The pharmacology of bimatoprost (lumigan™). Survey of Ophthalmology. 2001;45: s337–S345.
   PubMed Web of Science ®Google Scholar
• Nieminen T, Lehtimäki T, Mäenpää J, et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67(2):237–245.
   PubMed Web of Science ®Google Scholar
• Niño J, Tahvanainen K, Uusitalo H, et al. Cardiovascular effects of ophthalmic 0.5% timolol aqueous solution and 0.1% timolol hydrogel. Clin Physiol Funct Imaging. 2002;22(4):271–278.
   PubMed Web of Science ®Google Scholar
• Rouland J-F, Morel-Mandrino P, Elena P-P, et al. Timolol 0.1% gel (nyogel 0.1% once daily versus conventional timolol 0.5% solution twice daily: a comparison of efficacy and safety. Ophthalmologica. 2002;216(6):449–454.
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Bimatoprost/timolol fixed combination vs latanoprost/timolol fixed combination in open-angle glaucoma patients. Eye (Lond). 2009;23(4):810–818.
   PubMed Web of Science ®Google Scholar
• Katz LJ, Cohen JS, Batoosingh AL, et al. Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension. Am J Ophthalmol. 2010;149(4):661–671.e1.
   PubMed Web of Science ®Google Scholar